Overview

Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Intrapatient dose escalation study of desipramine in subjects with small cell lung cancer (SCLC) and other high-grade neuroendocrine tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Joel Neal
Treatments:
Desipramine